pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP191116
Phase 1 · other · hematologic malignancies ; acute myeloid leukemias
APHP191116 for hematologic malignancies ; acute myeloid leukemias is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP191116
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 1
- Modality
- other
- Indication
- hematologic malignancies ; acute myeloid leukemias
- Status
- active
- Trials
- 1